News

circle_logo2

CalciMedica Announces Publication of Preclinical Data in EMBO Molecular Medicine Supporting the Development of CRAC Channel Inhibitors for Inflammatory Bowel Disease (IBD)

– Study provides further validation of the potentially broad utility for CRAC channel inhibitors in inflammatory diseases– Data show that inhibiting store-operated Ca2+ entry (SOCE) …

CalciMedica Announces Publication of Results from CARDEA COVID-19 Study in Critical Care

– Results further support therapeutic potential of Auxora in respiratory diseases and other inflammatory diseases – LA JOLLA, Calif., April 14, 2022 – CalciMedica Inc. (CalciMedica …

CalciMedica Announces Publication of Peer-Reviewed Paper in The Journal of Physiology

Study Supports Development of CRAC Channel Inhibitors for Acute Pancreatitis Study indicates that Orai1 inhibition prevents impaired ductal cell function in acute pancreatitis (AP) Data …

CalciMedica Initiates CARDEA-Plus: A Clinical Trial of Auxora™ in Patients with Critical COVID-19 Pneumonia

CARDEA-Plus is designed to evaluate dosing, safety and efficacy of Auxora in combination with both tocilizumab and corticosteroids LA JOLLA, Calif., January 20, 2022 – CalciMedica …

CalciMedica Strengthens Board of Directors with Appointment of Finance Veteran Allan L. Shaw

LA JOLLA, Calif., November 2, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company), the CRAC channel company, today announced the appointment of Allan L. Shaw to …

Scroll to Top